Evidence map›Paper›PMID 36680530›Full record

ReviewTissue barriers2024

A comprehensive overview of advanced dynamic

Filipa Leal, Scarlett Zeiringer, Ramona Jeitler, Pedro F Costa, Eva Roblegg

Abstract readReview
In one paragraph

Review in Tissue barriers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Filipa LealBIOFABICS, Rua Alfredo Allen 455, 4200-135 Porto, Portugal.
Scarlett ZeiringerDepartment of Pharmaceutical Technology and Biopharmacy, University of Graz, Institute of Pharmaceutical Sciences, Universitaetsplatz 1, Graz, Austria.
Ramona JeitlerDepartment of Pharmaceutical Technology and Biopharmacy, University of Graz, Institute of Pharmaceutical Sciences, Universitaetsplatz 1, Graz, Austria.
Pedro F CostaBIOFABICS, Rua Alfredo Allen 455, 4200-135 Porto, Portugal.
Eva RobleggDepartment of Pharmaceutical Technology and Biopharmacy, University of Graz, Institute of Pharmaceutical Sciences, Universitaetsplatz 1, Graz, Austria.ORCID 0000-0002-5553-5147

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orally administered drugs pass through the gastrointestinal tract before being absorbed in the small intestine and metabolised in the liver. To test the efficacy and toxicity of drugs, animal models are often employed; however, they are not suitable for investigating drug-tissue interactions and making reliable predictions, since the human organism differs drastically from animals in terms of absorption, distribution, metabolism and excretion of substances. Likewise, simple static

Indexed as

HepatocytesLiverAnimalsCell Culture TechniquesHumansIntestinesMicrofluidicsbioprintinggastrointestinal tractintestineliverMicrofluidic devicesmulti-organ-on-a-chip

Identifiers

PMID36680530
PMCPMC10832944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.